Compound

TB Respiratory Chain

CSIR-Institute for Microbial Technology (IMTech), Johnson & Johnson
Names
Multiple candidates
Chemical Class:
Name of Target:
Mtb energy metabolism: Cytochromes BC / BD, NDH2, menaquinone
Description

New Delhi, August 16, 2017: Johnson & Johnson Private Limited today announced a new partnership with the Institute of Microbial Technology (IMTECH), part of the Council of Scientific and Industrial Research (CSIR), to unlock the potential of Indian science and help accelerate the discovery of innovative new treatments for tuberculosis (TB).

Under the Memorandum of Understanding, scientists from Johnson & Johnson’s global public health team will work closely with scientists from CSIR-IMTECH, based in Chandigarh, India, on a research and development program to explore potentially more effective, safer, all-oral treatment regimens to tackle multidrug-resistant TB (MDR-TB), as well as new molecular entities to treat all TB patients. 

Director, CSIR-IMTech is Dr. Anil Koul who was a key scientist in discovery and clinical development of SIRTURO (Bedaquiline) as Senior Director & Head, Respiratory Infections Discovery group at Johnson & Johnson.